Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002) - Yahoo Finance

Submitted by Anonymous (not verified) on Wed, 11/20/2019 - 14:00

Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)  Yahoo Finance